Download the Protocol

5-Amino-1MQ

5-Amino-1MQ is a small compound studied for helping the body use energy more efficiently. It is thought to support healthy weight balance and improve how cells handle energy, but it has not been officially tested or approved for use in people.

Description

• 5-Amino-1MQ is a small-molecule compound that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme linked to fat storage and metabolic regulation.
• It is not a peptide but is often grouped with metabolic-modulating research compounds.
• Studied for its potential to improve energy metabolism, promote fat loss, and enhance insulin sensitivity.

How It Works

• Inhibits NNMT, an enzyme that consumes nicotinamide (a precursor of NAD⁺).
• By blocking NNMT, 5-Amino-1MQ increases cellular NAD⁺ levels and boosts metabolic activity.
• Enhances energy utilization in adipose and muscle tissues, potentially supporting lean mass maintenance during fat reduction.

Documented Effects

• In preclinical models, reduced body fat and improved insulin response without major dietary changes.
• Improved mitochondrial efficiency and fatty acid oxidation in adipocytes.
• No major toxicity observed in short-term animal trials.

Theoretical Effects

• May support weight management and body composition optimization.
• Potential to enhance cellular energy metabolism through NAD⁺ preservation.
• Possible synergy with NAD⁺ precursors such as NMN or NR (research-phase only).
• No human clinical data confirming efficacy or safety.

Pharmacokinetics

• Half-life: approximately 3–5 hours in preclinical studies.
• Peak concentration: typically reached within 1–2 hours after administration.
• Steady-state: may occur after 2–3 days of consistent dosing in animal models.

Duration of Effects

• Metabolic effects may last 6–12 hours per dose based on limited data.
• Changes in energy metabolism could persist for several days after discontinuation in short-term studies.
• Long-term persistence of effects is not established.

Reconstitution

• For research use only; typically supplied as lyophilized or crystalline powder.
• Example vial: 50 mg 5-Amino-1MQ
• Use sterile bacteriostatic water or DMSO for dissolution (based on intended research medium):
  • 1 mL water → 50 mg/mL → 5 mg per 10 units
  • 5 mL water → 10 mg/mL → 1 mg per 10 units
  • 10 mL water → 5 mg/mL → 500 mcg per 10 units
• Mix gently to dissolve completely.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Research Context)

Typical Experimental Range

• Animal studies often use doses equivalent to 50–100 mg/day adjusted by body weight (no established human equivalent).
• Compounded human “research-use” preparations sometimes reported at 25–50 mg SC once daily (unverified, anecdotal).

Cycle Duration

• Common experimental periods range from 2–6 weeks.
• Cycles are typically followed by washout periods to assess reversibility of metabolic effects.

Clinical Notes

• Commonly studied as a once-daily subcutaneous or oral compound in experimental contexts.
• No standardized tapering or stacking protocols exist; combining with NAD⁺ boosters remains unverified.
• Stable in cool, dry conditions; degraded by light and prolonged exposure to moisture.
• Should be handled and stored under laboratory-grade conditions only.

Safety Notes

• Research compound; not approved for medical or human use.
• Potential side effects (theoretical): fatigue, mild headaches, or appetite reduction due to metabolic shift.
• Long-term safety data are unavailable.
• Handle using standard laboratory safety procedures.